The US Federal Trade Commission doubled down on its efforts to halt the close of Amgen, Inc.’s proposed acquisition of Horizon Therapeutics plc until a final decision is made on its administrative complaint opposing the deal, asking a district court to issue a preliminary injunction by 31 October.
In a redacted 14 July memorandum supporting a preliminary injunction, the FTC and six states reiterated that post-merger, Amgen will be able to use rebates on its blockbuster drugs...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?